B 
Beijing Sun-Novo Pharmaceutical Research Co 688621.SS · CNY
Health Care · Shanghai · 🇨🇳 China
51.92
-2.48%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥1.22bn
FY2017FY2025
Net income
CN¥196.1m
FY2017FY2025
Free cash flow
CN¥50.8m
FY2017FY2025
Shareholders' equity
CN¥1.22bn
FY2017FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.22bn | CN¥1.08bn | CN¥932.1m | CN¥676.6m | CN¥493.6m | CN¥347.4m | CN¥233.5m | CN¥134.8m | CN¥36.0m |
| Research and development | CN¥161.6m | CN¥171.9m | CN¥123.7m | CN¥89.7m | CN¥47.6m | CN¥34.2m | CN¥19.1m | CN¥8.5m | CN¥2.8m |
| Operating income | CN¥204.2m | CN¥177.7m | CN¥194.2m | CN¥169.3m | CN¥122.6m | CN¥82.8m | CN¥55.0m | CN¥23.6m | CN¥1.2m |
| Net income | CN¥196.1m | CN¥177.4m | CN¥184.8m | CN¥156.5m | CN¥105.7m | CN¥72.5m | CN¥47.4m | CN¥20.7m | CN¥2.0m |
| Diluted earnings per share | 1.79 | 1.58 | 1.64 | 1.41 | 0.75 | 0.87 | 0.43 | 0.19 | 0.02 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥2.28bn | CN¥1.99bn | CN¥1.86bn | CN¥1.46bn | CN¥1.24bn | CN¥384.9m | CN¥285.5m | CN¥201.5m | CN¥110.1m |
| Cash and short-term investments | — | CN¥595.6m | CN¥720.9m | CN¥622.0m | CN¥647.9m | CN¥109.3m | CN¥76.5m | CN¥31.7m | CN¥5.6m |
| Total liabilities | CN¥1.05bn | CN¥884.7m | CN¥805.8m | CN¥554.9m | CN¥473.0m | CN¥191.9m | CN¥166.8m | CN¥127.7m | CN¥76.8m |
| Debt | CN¥48.0m | CN¥411.7m | CN¥424.6m | CN¥257.6m | CN¥206.7m | CN¥23.5m | CN¥15.9m | CN¥4.9m | CN¥24.6m |
| Shareholders' equity | CN¥1.22bn | CN¥1.10bn | CN¥1.04bn | CN¥896.7m | CN¥761.9m | CN¥189.1m | CN¥116.6m | CN¥75.2m | CN¥34.1m |
| Shares outstanding | 109m | 112m | 112m | 111m | 140m | 83m | 109m | 109m | 109m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥93.2m | CN¥32.0m | CN¥92.9m | CN¥104.0m | CN¥88.3m | CN¥63.0m | CN¥57.0m | CN¥44.1m | CN¥8.0m |
| Capital spending | −CN¥42.4m | −CN¥30.5m | −CN¥73.0m | −CN¥103.9m | −CN¥85.0m | −CN¥27.0m | −CN¥25.7m | −CN¥16.4m | −CN¥21.0m |
| Free cash flow | CN¥50.8m | CN¥1.5m | CN¥19.9m | CN¥91,919 | CN¥3.3m | CN¥36.0m | CN¥31.3m | CN¥27.7m | −CN¥12.9m |
| Dividends paid | −CN¥32.3m | −CN¥38.2m | −CN¥55.5m | −CN¥21.2m | −CN¥1.2m | −CN¥1.1m | −CN¥306,240 | −CN¥1.1m | −CN¥507,500 |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥229.0m | CN¥197.1m | CN¥362.1m | CN¥265.5m | CN¥359.5m | CN¥230.8m | CN¥161.8m | CN¥353.8m |
| Operating income | CN¥12.3m | CN¥12.5m | CN¥34.5m | CN¥32.3m | CN¥114.0m | CN¥23.4m | −CN¥41.6m | CN¥65.8m |
| Net income | −CN¥45.0m | CN¥20.6m | CN¥32.8m | CN¥33.5m | CN¥100.3m | CN¥29.6m | −CN¥30.3m | CN¥59.1m |
| Diluted earnings per share | -0.41 | 0.19 | 0.30 | 0.31 | 0.92 | 0.27 | -0.27 | 0.53 |
| Cash from operations | — | — | — | CN¥76.0m | CN¥73.0m | CN¥10.0m | −CN¥73.0m | CN¥172.0m |
| Capital spending | −CN¥7.0m | −CN¥4.0m | −CN¥26.0m | −CN¥4.0m | −CN¥6.0m | −CN¥4.0m | −CN¥8.0m | — |
| Free cash flow | — | — | — | CN¥72.0m | CN¥67.0m | CN¥6.0m | −CN¥81.0m | — |
| Total assets | CN¥2.26bn | CN¥2.30bn | CN¥2.28bn | CN¥2.21bn | CN¥2.20bn | CN¥2.14bn | CN¥1.99bn | CN¥2.08bn |
| Cash and short-term investments | — | — | — | CN¥706.4m | CN¥674.6m | CN¥670.6m | CN¥595.6m | CN¥694.2m |
| Debt | CN¥38.4m | CN¥38.4m | CN¥48.0m | CN¥522.5m | CN¥524.5m | CN¥543.7m | CN¥376.6m | CN¥422.0m |
| Shareholders' equity | CN¥1.20bn | CN¥1.25bn | CN¥1.22bn | CN¥1.16bn | CN¥1.12bn | CN¥1.03bn | CN¥1.10bn | CN¥1.13bn |
Financial ratios
Data as of 10 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | 16.5% | 17.8% | 22.1% | 26.5% | 25.5% | 24.0% |
| Net margin | 16.1% | 16.5% | 19.8% | 23.1% | 21.4% | 20.9% |
| Return on equity | 16.1% | 16.1% | 17.8% | 17.4% | 13.9% | 38.3% |
| Return on assets | 8.6% | 8.9% | 9.9% | 10.7% | 8.5% | 18.8% |
| Free cash flow yield | 1.8% | 0.8% | 2.2% | 2.8% | 1.8% | 1.6% |
| Revenue growth | 12.9% | 15.7% | 37.8% | 37.1% | 42.1% | 48.7% |
| Earnings growth | 10.5% | -4.0% | 18.1% | 48.1% | 45.8% | 52.9% |
| Current ratio | 1.80x | 1.95x | 1.78x | 2.01x | 2.25x | 1.37x |
| Debt to equity | 0.04x | 0.34x | 0.37x | 0.22x | 0.18x | -0.64x |
| Equity ratio | 53.3% | 55.4% | 55.8% | 61.3% | 61.3% | 49.1% |
| Interest coverage | 12.22x | 11.89x | 16.81x | 18.12x | 34.82x | 80.11x |
| R&D as a share of sales | 13.3% | 15.9% | 13.3% | 13.3% | 9.6% | 9.8% |
| Buybacks as a share of market value | 2.6% | 0.1% | -1.5% | 20.9% | -67.8% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 21.6% | 28.5% | — |
| Operating income | 6.5% | 19.8% | — |
| Net income | 7.8% | 22.0% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Price to earnings | 34.7 | 23.9 | 42.5 | 51.8 | 115.1 |
| Price to sales | 5.6 | 3.9 | 8.4 | 12.0 | 24.6 |
Dividends and splits
Per share, in the currency the company pays
Paid for 4 years. Last went ex-dividend on 29 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Paid in the year | 0.187 | 0.163 | 0.165 | 0.60 | 0.189 |
- 7-for-5 split · 12 May 2023
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.